LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Jul 30, 2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025
88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval
Read more at globenewswire.comNASDAQ:LENZ (12/3/2025, 3:48:48 PM)
27.85
+0.54 (+1.98%)
Find more stocks in the Stock Screener
